Literature DB >> 1393259

Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action.

Y J Liu1, N P Shankley, N J Welsh, J W Black.   

Abstract

1. The interactions between angiotensin II (AII), two non-peptide antagonists DuP 753 and IMI, and eight peptide analogues of AII were investigated on the rabbit isolated aorta assay. DuP 753 and IMI behaved as simple competitive antagonists (pKB values 8.4 and 6.8, respectively). To different degrees, all the AII-peptide analogue interactions failed to meet the basic criteria for simple competition. In addition to rightward shift, the most significant feature was a concentration-dependent saturable depression of the upper asymptote of the AII concentration-effect curves. 2. 'Washout' and combined dose-ratio analysis experiments, in which DuP 753 was used as a reference antagonist, indicated that the profile of peptide antagonism was solely due to a reversible and syntopic action at the AII receptor. 3. By use of an operational model of agonism (Black & Leff, 1983) as a starting point, it was possible to account for the data with a new model which describes reversible receptor occupancy and occupied receptor-determined, saturable reduction in the efficacy of AII. Model-fitting gave estimates of pKB values for the peptide analogues and agonist affinity and efficacy parameters for AII. 4. The model was successfully tested by applying it to qualitatively similar results obtained in a cross-tissue analysis on guinea-pig aorta, ileum and stomach. 5. A 'molecular' interpretation of the efficacy changes, based on the concepts of receptor internalisation and expression, is offered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393259      PMCID: PMC1907508          DOI: 10.1111/j.1476-5381.1992.tb14322.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE.

Authors:  H P RANG
Journal:  Br J Pharmacol Chemother       Date:  1964-04

2.  A new, long-lasting competitive inhibitor of angiotensin.

Authors:  R K Türker; M M Hall; M Yamamoto; C S Sweet; F M Bumpus
Journal:  Science       Date:  1972-09-29       Impact factor: 47.728

3.  A specific competitive inhibitor of angiotensin II.

Authors:  G R Marshall; W Vine; P Needlemann
Journal:  Proc Natl Acad Sci U S A       Date:  1970-11       Impact factor: 11.205

4.  Correlation between log POCT/H2O and pKB estimates for a series of muscarinic and histamine H2-receptor antagonists.

Authors:  N P Shankley; J W Black; C R Ganellin; R C Mitchell
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

5.  Use of selective antagonists for determining the types of receptors mediating the actions of 5-hydroxytryptamine and tryptamine in the isolated rabbit aorta.

Authors:  J S Stollak; R F Furchgott
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

6.  An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation.

Authors:  J W Black; P Leff; N P Shankley; J Wood
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

7.  Organ selective angiotensin antagonists: sarcosyl1-cysteinyl(S-methyl)8-angiotensin I.

Authors:  R J Freer; J C Sutherland; A R Day
Journal:  Eur J Pharmacol       Date:  1980-08-08       Impact factor: 4.432

8.  A new approach to angiotensin antagonists: methylation of the tyrosine hydroxyl in angiotensin II.

Authors:  M N Scanlon; J M Matsoukas; K J Franklin; G J Moore
Journal:  Life Sci       Date:  1984-01-23       Impact factor: 5.037

9.  Potassium depletion selectively inhibits sustained diacylglycerol formation from phosphatidylinositol in angiotensin II-stimulated, cultured vascular smooth muscle cells.

Authors:  P Delafontaine; K K Griendling; M A Gimbrone; R W Alexander
Journal:  J Biol Chem       Date:  1987-10-25       Impact factor: 5.157

10.  Classification of angiotensin receptors in rat isolated uterus, portal vein, and aorta using a slowly dissociating antagonist [Sar1,Ile8]ANG II for receptor blockade.

Authors:  M N Scanlon; G J Moore
Journal:  J Pharmacol Methods       Date:  1988-11
View more
  12 in total

1.  Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.

Authors:  P M Vanderheyden; I Verheijen; F L Fierens; J P DeBacker; G Vauquelin
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.

Authors:  Simeon J Ramsey; Neil J Attkins; Rebecca Fish; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.

Authors:  P M Vanderheyden; F L Fierens; J P De Backer; N Fraeyman; G Vauquelin
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.

Authors:  R A Hull; N P Shankley; E A Harper; V P Gerkowitch; J W Black
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

5.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

6.  Analysis of the CCKB receptor antagonism of virginiamycin in guinea-pig ileum longitudinal myenteric plexus.

Authors:  M Corsi; G Pojani; G Dal Forno; C Pietra; G Gaviraghi; D Trist
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.

Authors:  M J Robertson; J C Barnes; G M Drew; K L Clark; F H Marshall; A Michel; D Middlemiss; B C Ross; D Scopes; M D Dowle
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

9.  BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.

Authors:  K E Dickinson; R B Cohen; S Skwish; C L Delaney; R P Serafino; M A Poss; Z Gu; D E Ryono; S Moreland; J R Powell
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

10.  Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

Authors:  A Hilditch; A A Hunt; C J Gardner; D J Twissell; J Polley; A Travers; G M Drew; D Middlemiss; B C Ross; M J Robertson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.